英文【Jefferies】专家证实Ohtuvayre的广泛应用场景-峰值销售额可能超过30亿美元

报告摘要

USA | Biotechnology Expert Confirms Ohtuvayre's Broad Use Case Probable Upside to $3B+ Peak Sales Dr. Adam Smith, who treats 1,800+ COPD patients per year, has prescribed

核心要点

2025 ($)
0.04
0.06
0.08
0.16
1.22
2.85
403.9

报告信息

文件全名: 《英文【Jefferies】专家证实Ohtuvayre的广泛应用场景-峰值销售额可能超过30亿美元-17页.pdf》
适合读者: 战略规划行业研究员
核心数据: Ohtuvayre (novel PDE3/4 nebulizer) to 55 of his pts (3%), which should rise
towards 100+ by YE:25 (6%) before steadily climbing to 200 at peak (11%) making our $3B+ peak sales seem quite conservative (on a smaller <3% market
with 50%+ of his Ohtuvayre patients already having shared (+) feedback.
$115.00 ($110.00)
+25%
核心议题: 管理咨询

常见问题

《英文【Jefferies】专家证实Ohtuvayre的广泛应用场景-峰值销售额可能超过30亿美元》主要包含哪些内容?

USA | Biotechnology Expert Confirms Ohtuvayre's Broad Use Case Probable Upside to $3B+ Peak Sales Dr. Adam Smith, who treats 1,800+ COPD patients per year, has prescribed核心数据:Ohtuvayre (novel PDE3/4 nebulizer) to 55 of his pts (3%), which should rise;towards 100+ by YE:25 (6%) before steadily climbing to 200 at peak (11%) making our $3B+ peak sales seem quite conservative (on a smaller <3% market;with 50%+ of his Ohtuvayre patients already having shared (+) feedback.。

这份报告覆盖哪一年、篇幅多大?

覆盖 2025 年,全文约 17。

这份报告是免费的吗?如何获取?

本报告免费查阅,登录资料宝后即可在线获取完整内容。

这份报告适合哪些读者?

适合战略规划、行业研究员等读者参考。

报告涉及哪些关键议题?

重点分析了管理咨询等议题。